Frederic Pla compensation by year
Akoya Biosciences Summary Compensation Table · the one fiscal year held| Component | FY2023 |
|---|---|
| Salary | $414,167 |
| Bonus | $0 |
| Stock awards | $360,000 |
| Option awards | $270,153 |
| Non-equity incentive | $156,375 |
| Pension and deferred compensation | $0 |
| All other | $10,690 |
| Total | $1,211,385 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Akoya Biosciences, Inc. DEF 14A filed April 23, 2024, accession 0001104659-24-050208, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Akoya Biosciences, Inc. filed document, accession 0001104659-24-050208. Every figure is read from that document and cited to the page and table it appears in. Filed April 23, 2024.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 30,000 | $146,400 | — |
| RSU | 20,000 | $97,600 | — |
| RSU | 16,875 | $82,350 | — |
| Option | 113,998 | — | $16.12 |
| Option | 25,313 | — | $11.88 |
| Option | 40,000 | — | $12.30 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Akoya Biosciences, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.
Akoya Biosciences’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Brian McKelligon | Chief Executive Officer | $2,919,599 |
| Johnny Ek | Chief Financial Officer | $2,309,744 |
| Frederic Pla · this page | Chief Operating Officer | $1,211,385 |
The full Akoya Biosciences compensation record
free company briefThis page is one person within Akoya Biosciences's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Akoya Biosciences's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.